HI-P260

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: HI-P260
• 英文别名: (4-bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)amine hydrochloride；4-N-(4'-bromo-phenyl)amino-6,7-dimethoxyquinazoline hydrochloride；6, 7-dimethoxy-4-N-(4'-bromo) phenylaminequinazoline hydrochloride；N-(4-bromophenyl)-6,7-dimethoxyquinazolin-4-amine;hydrochloride
• 化学式: C₁₆H₁₄BrN₃O₂*ClH
• 分子量: 396.671
• InChiKey: CIYFLJIYFFUDNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.57
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  56.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  HI-P260 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 21.0h， 以35%的产率得到4-(N-methyl-4-bromoanilino)-6,7-dimethoxyquinazoline
  参考文献：
  名称：

  Design, Synthesis, and DNA-Binding of N-Alkyl(anilino)quinazoline Derivatives

  摘要：

  New N-alkylanilinoquinazoline derivatives 5, 12, 20, and 22 have been prepared Crow 4-chloro-6, 7-dimethoxyquinazoline 3, 4-chloro-6,7-methylenedioxyquinazoline 19, and commercially available anilines. Differents classes of compounds substituted by an aryloxygroup (6a-c. 16a,b, and 17a,b). (aminophenyl)ureas (12a,b and 13a-f), anilines (4a-m, 20a,b), N-alkyl(aniline) (5a-m, 21a,b. 22a,d). and N-aminoalkyl(aniline) (22e-g) have been synthesized. These molecules were evaluated for then. cytotoxic activities and as potential DNA intercalating agents. We studied the strength and mode of binding to DNA of these molecules by DNA melting temperature measurements, fluorescence emission. and circular dichroism. The results of various spectral and gel electrophoresis techniques obtained with the different compounds, in particular compounds 5g and 22f, revealed significant DNA interaction. These experiments confirm that the N-aminoalkyl(anilino)-6,7-dimethoxyquinazoline nucleus is an efficient pharmacophore to trigger binding to DNA, via an intercalative binding process.

  DOI：

  10.1021/jm1009605
• 作为产物：
  描述：

  2-氨基-4,5-二甲氧基苯甲酸 在 氯化亚砜 作用下， 以 异丙醇 为溶剂， 反应 8.0h， 生成 HI-P260
  参考文献：
  名称：

  一些4-苯胺基喹唑啉衍生物的合成

  摘要：

  一些4-N-(3'-或4'-取代-苯基)氨基-6,7-二甲氧基喹唑啉和相应的未取代化合物由2-氨基-4,5-二甲氧基苯甲酸和适当的取代苯胺合成。还获得了其他相关的喹唑啉或其合成中间体。大量描述的喹唑啉是新化合物，而其余的则通过更有效的方法制备。合成这些化合物的主要目标是 4-苯胺基喹唑啉药效团是一个重要的单元，它存在于几种蛋白激酶的 ATP 竞争性抑制剂中。

  DOI：

  10.1055/s-2004-815949

文献信息

• 4-Anilinequinazolines with adenosine-kiase inhibitor properties
  申请人：Franchini Gomes Kleber

  公开号：US20070060600A1

  公开（公告）日：2007-03-15

  The present invention relates to the use of 4-anilinoquinazoline derivatives as adenosine-kinase inhibitors. The present invention also relates to a method for protecting tissues and organs like heart, brain and kidneys affected by ischemia, and for treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery restenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflanunatory diseases (e.g., rheumatoid arthritis). The present invention also relates to the compound 6,7-dimethoxy-4-(3′-N′,N′-dimethylaminoanilino)quinazoline, or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising it and use of such compound in the manufacture of a medicament for treating or preventing diseases or conditions that are benefited from the adenosine-kinase inhibition.

  本发明涉及使用4-苯胺基喹唑啉衍生物作为腺苷激酶抑制剂。本发明还涉及一种保护受缺血影响的心脏、脑和肾等组织和器官，并治疗心力衰竭、心肌梗塞、心律失常、动脉高血压、动脉粥样硬化、血管成形术后冠状动脉再狭窄、慢性肾功能不全、脑血管意外和慢性炎症性疾病（如类风湿性关节炎）的方法。本发明还涉及化合物6,7-二甲氧基-4-(3'-N',N'-二甲基氨基苯基)喹唑啉或其药学上可接受的盐、包含它的制药组合物以及使用该化合物制造治疗或预防从腺苷激酶抑制中受益的疾病或病情的药物的用途。
• Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors
  作者：Su Hui Yang、Daulat Bikram Khadka、Suk Hee Cho、Hye-Kyung Ju、Kwang Youl Lee、Ho Jae Han、Kyung-Tae Lee、Won-Jea Cho

  DOI：10.1016/j.bmc.2010.11.057

  日期：2011.1

  JAK2 is an important target in multiple processes associated with tumor growth. In this study, virtual screening was employed for hit compound identification with chemical libraries using SurflexDock. Subsequently, hit optimization for potent and selective candidate JAK2 inhibitors was performed through synthesis of diverse C-1 substituted quinazoline derivatives. A novel compound 5p, (6,7-dimethoxyquinazolin-4-yl)naphthalen-1-ylamine, was thus obtained. JAK2 inhibitory activity of 5p was 43% at 20 mu M and this was comparable to AG490, a representative JAK2 inhibitor. Moreover, 5p showed a positive correlation between JAK2 inhibition and cytotoxicity; 5p treatment in HT-29 cells strongly inhibited JAK2 activation and subsequent STAT3 phosphorylation, reduced anti-apoptotic protein levels, and finally induced apoptosis. This suggests that compound 5p is a candidate inhibitor of JAK2 and its downstream STAT3 signaling pathway for antitumor therapy. In the docking model, the quinazoline template of 5k, the lead compound, occupied a hydrophobic region such as Leu856, Leu855, Ala880, Leu932 and Gly935, and the highly conserved hydrogen bond was created by 6-OMe of the ring template, which binds to the NH of Arg980. Moreover, hydrophobic interactions were identified between morpholine moiety and the hydrophobic region formed by Leu855, Ala880, Tyr931, Val911 and Met929. Also, compound 5k more strongly inhibited JAK2 phosphorylation in mouse embryonic stem cells than AG490. Our study shows the successful application of virtual screening for lead discovery and we propose that the novel compound 5p can be an effective JAK2 inhibitor candidate for further antitumor agent research. (C) 2010 Elsevier Ltd. All rights reserved.
• 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES
  申请人：UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP

  公开号：EP1737832B1

  公开（公告）日：2011-12-14
• US8513267B2
  申请人：——

  公开号：US8513267B2

  公开（公告）日：2013-08-20